Newsfeeds - Spark Newswire

2 minute read

ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired By Distinguished Dermatology Expert Dr Lawrence Eichenfield

Today, 4:58 PM

ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence

ASLN

4 minute read

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:58 PM

Gainers Focus Universal Inc. (NASDAQ: FCUV) shares climbed 278% to close at $19.28 on Wednesday. The stock started trading on Nasdaq Capital Market yesterday.

AAMC

1 minute read

ASLAN Pharmaceuticals Q2 EPS $(0.08) Up From $(0.10) YoY

By Benzinga Newsdesk

Today, 4:58 PM

ASLAN Pharmaceuticals (NASDAQ:ASLN) reported quarterly losses of $(0.08) per share. This is a 20 percent increase over losses of $(0.10) per share from the same period last year.

ASLN

1 minute read

Movers

12 Health Care Stocks Moving In Monday’s After-Market Session

By Benzinga Insights

Today, 4:58 PM

Gainers

ADTX

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 4:58 PM

Gainers

AKBA

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

Today, 4:58 PM

Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap stands at $87.4 million.

ASLN

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For July 9, 2021

By Benzinga Insights

Today, 4:58 PM

h2>Upgrades

ALGN

1 minute read

Jefferies Initiates Coverage On ASLAN Pharmaceuticals with Buy Rating, Announces Price Target of $8

By Benzinga Newsdesk

Today, 4:58 PM

Jefferies analyst Maury Raycroft initiates coverage on ASLAN Pharmaceuticals (NASDAQ:ASLN) with a Buy rating and announces Price Target of $8.

ASLN

5 minute read

60 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:58 PM

Gainers RAPT Therapeutics, Inc. (NASDAQ: RAPT) shares jumped 115.5% to settle at $40.02 on Monday as the company announced topline results from its Phase 1b trial of RPT193 as monotherapy for moderate-to-severe atopic dermatitis (AD).

AMC

1 minute read

Uncategorized

ASLAN Pharmaceuticals Q1 EPS $(0.02), Same YoY

By Bill Haddad

Today, 4:58 PM

ASLAN Pharmaceuticals (NASDAQ:ASLN) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year.

ASLN